Drug prices improved under Biden-Harris and Trump –

but not enough for everyone.”

The impact of the drug negotiations has been modest at best. There is a lot of talk and hurrahs. The results are not there yet. When I go to the outside for care, the VA pays the doctors at a minimum. If they want VA patients, them they accept minimal payments. If the VA disappeared those minimal payments would disappear. Like healthcare, pharmaceuticals are costly (a polite way of saying overpriced). I have a post somewhere discussing the ICER review of the top 10 in pricing. I also have a report using MedPac information too. I just have not finished them up to present.

The following? It is just a review of what id going on or has been going on in healthcare. It is discussing recent achievements.

~~~~~~~

When it comes to drug pricing, the Trump and Biden-Harris administrations both have some very modest wins to tout.

Delving into the presidential candidates’ successes on a number of drug-pricing policies, you’ll see a continuation of progress across the administrations. Neither the Trump administration nor the Biden-Harris administration has done anything to truly lower drug prices for the majority of Americans.

$35 insulin

Importing Canadian drugs

Negotiating with the pharmaceutical industry

Prices will be negotiated for another 15 Medicare Part D drugs in 2027. Thereafter, drug negotiations could include Medicare Part D drugs, which you pick up from your pharmacy, and Medicare Part B drugs, which are administered or received from your doctor’s office.

It is often challenging to attribute policy successes to one administration versus another when assessing complex issues such as drug pricing. There were ideas initiated during the Trump administration that did not come to fruition until the Biden-Harris administration implemented and expanded on them.

For example, Medicare price negotiation, proposed in a Trump administration “blueprint,” was codified in law by President Biden, but the fruits of this policy will not be seen until the next administration. And regardless of who you attribute this success to, only a portion of people on Medicare will see any relief from high drug prices as a result.